Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16864853rdf:typepubmed:Citationlld:pubmed
pubmed-article:16864853lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:16864853lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:16864853lifeskim:mentionsumls-concept:C0280803lld:lifeskim
pubmed-article:16864853lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:16864853lifeskim:mentionsumls-concept:C1708063lld:lifeskim
pubmed-article:16864853lifeskim:mentionsumls-concept:C1328050lld:lifeskim
pubmed-article:16864853pubmed:issue24lld:pubmed
pubmed-article:16864853pubmed:dateCreated2006-8-21lld:pubmed
pubmed-article:16864853pubmed:abstractTextTo improve survival and reduce toxicity in primary CNS lymphoma (PCNSL) treatment, we conducted a multicenter phase II study with early high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) followed by hyperfractionated whole-brain radiotherapy (WBRT) for newly diagnosed PCNSL patients younger than 65 years of age.lld:pubmed
pubmed-article:16864853pubmed:languageenglld:pubmed
pubmed-article:16864853pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16864853pubmed:citationSubsetIMlld:pubmed
pubmed-article:16864853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16864853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16864853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16864853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16864853pubmed:statusMEDLINElld:pubmed
pubmed-article:16864853pubmed:monthAuglld:pubmed
pubmed-article:16864853pubmed:issn1527-7755lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:FinkeJürgenJlld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:FrickhofenNor...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:GuttenbergerR...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:VolkBenediktBlld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:OstertagChris...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:IhorstGabriel...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:FeuerhakeFrie...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:MarksReinhard...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:IllerhausGera...lld:pubmed
pubmed-article:16864853pubmed:authorpubmed-author:DerigsGünther...lld:pubmed
pubmed-article:16864853pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16864853pubmed:day20lld:pubmed
pubmed-article:16864853pubmed:volume24lld:pubmed
pubmed-article:16864853pubmed:ownerNLMlld:pubmed
pubmed-article:16864853pubmed:authorsCompleteYlld:pubmed
pubmed-article:16864853pubmed:pagination3865-70lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:meshHeadingpubmed-meshheading:16864853...lld:pubmed
pubmed-article:16864853pubmed:year2006lld:pubmed
pubmed-article:16864853pubmed:articleTitleHigh-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.lld:pubmed
pubmed-article:16864853pubmed:affiliationDepartment of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany.lld:pubmed
pubmed-article:16864853pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16864853pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16864853pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16864853lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16864853lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16864853lld:pubmed